Date,Text
2016-02-26,"As high costs draw attention from lawmakers, 2016 candidates and the public, drug companies are anxious about regulations the administration may be brewing up. In other pharmaceutical news, McKesson acquires two cancer-focused firms, and the newly confirmed head of the Food and Drug Administration talks to The Washington Post about the battle over his ties to the industry. The Hill:
						Drug Industry On Edge For Obama Action On Prices					

					The pharmaceutical industry is anxiously awaiting a series of regulatory actions from the Obama administration aimed at combating high drug prices. Drug prices have been a major issue on the campaign trail, with Hillary Clinton and Bernie Sanders pounding pharmaceutical companies. (Sullivan, 2/26) The Wall Street Journal:
						McKesson To Buy Two Cancer-Focused Firms For $1.2 Billion					

					McKesson Corp. agreed to acquire cancer-care company Vantage Oncology LLC and oncology pharmacy-services firm Biologics Inc. in separate deals with a combined value of roughly $1.2 billion. McKesson’s shares rose 3.5% to $160.08 in recent premarket trading. The San Francisco company said the acquisitions will expand the scale of its specialty-drug distribution operations and increase its other capabilities, including its cancer-focused pharmacy offerings. (Stynes, 2/25) The Washington Post:
						New FDA Head Robert Califf Vows To Use ‘Bully Pulpit,’ Better Explain Agency Decisions					

					Robert Califf, a longtime Duke University cardiologist and researcher, was confirmed as the next leader of the Food and Drug Administration this week by a wide margin. The Senate voted 89 to 4 in favor of placing Califf in the agency's top post, where he replaces former FDA commissioner Margaret A. Hamburg. ... Aside from a confirmation hearing last fall, in which he defended his past work and said he had no intentions of lowering the FDA's standards for safety and effectiveness of drugs and devices, Califf largely remained silent. But after winning confirmation Wednesday, he spoke in a brief interview with the Post about his priorities as FDA commissioner. (Dennis, 2/25) We want to hear from you: Contact Us Hospitals Fighting Measles Confront a Challenge: Few Doctors Have Seen It Before Listen to the Latest ‘KFF Health News Minute’ As More Americans Embrace Anxiety Treatment, MAHA Derides Medications New Orleans Brings Back the House Call, Sending Nurses To Visit Newborns and Moms © 2026 KFF. All rights reserved. Powered by WordPress VIP Thank you for your interest in supporting KFF Health News, the nation’s leading nonprofit newsroom focused on health and health policy. We distribute our journalism for free and without advertising through media partners of all sizes and in communities large and small. We appreciate all forms of engagement from our readers and listeners, and welcome your support. KHN is an editorially independent program of KFF (Kaiser Family Foundation). You can support KHN by making a contribution to KFF, a non-profit charitable organization that is not associated with Kaiser Permanente. Click the button below to go to KFF’s donation page which will provide more information and FAQs. Thank you!"
